Pharma Spent More Than $48B in China in H1, Eclipsing Total 2024 Haul

By /

If the trend holds, IQVIA expects 2025 deal volume between Chinese and multinational companies to easily eclipse the 100 agreements signed in 2024.

Scroll to Top